TCGA-05-4427-01A-21R-1858-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.490
- PROTEIN_SECRETION+0.420
- G2M_CHECKPOINT+0.380
- TGF_BETA_SIGNALING+0.320
- INTERFERON_ALPHA_RESPONSE+0.310
- PI3K_AKT_MTOR_SIGNALING+0.300
- E2F_TARGETS+0.290
- INTERFERON_GAMMA_RESPONSE+0.260
- UV_RESPONSE_DN+0.240
- TNFA_SIGNALING_VIA_NFKB+0.190
Top 10 suppressed
- KRAS_SIGNALING_DN-0.380
- OXIDATIVE_PHOSPHORYLATION-0.340
- XENOBIOTIC_METABOLISM-0.290
- MYC_TARGETS_V2-0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.240
- ESTROGEN_RESPONSE_LATE-0.230
- MTORC1_SIGNALING-0.210
- PANCREAS_BETA_CELLS-0.210
- GLYCOLYSIS-0.200
- MYOGENESIS-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3043 | Med | Medulloblastoma | 0.799 |
| 2 | MNG746 | — | — | 0.759 |
| 3 | MDT-AP-3199 | Med | Medulloblastoma | 0.754 |
| 4 | MNG611 | — | — | 0.753 |
| 5 | TCGA-D8-A1Y0-01A-11R-A14M-07 | — | A | 0.751 |
| 6 | MNG642 | — | — | 0.750 |
| 7 | TCGA-55-7994-01A-11R-2187-07 | — | cohortA1 | 0.725 |
| 8 | SJEPD030584_D1.RNA-Seq | EPN | Supratentorial EPN | 0.723 |
| 9 | MNG724 | — | — | 0.716 |
| 10 | MDT-AP-3329 | Med | Medulloblastoma | 0.715 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.490 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.420 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.310 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.180 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.160 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.120 | Inavolisib | — uncovered |
| APOPTOSIS | 0.110 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.060 | Idelalisib | — uncovered |
| COMPLEMENT | 0.030 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.020 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.010 | Inavolisib | — uncovered |